Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay

Cancer Research

Volumn 74, Issue 8, 2014, Pages 2152-2159

  MacArthur, Kelly M ^a   Kao, Gary D ^a   Chandrasekaran, Sanjay ^a   Alonso Basanta, Michelle ^a   Chapman, Christina ^a   Lustig, Robert A ^a   Wileyto, E Paul ^b   Hahn, Stephen M ^a   Dorsey, Jay F ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE; NESTIN; TELOMERASE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN TUMOR; CIRCULATING TUMOR CELL; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; INTENSITY MODULATED RADIATION THERAPY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTON THERAPY; TUMOR GROWTH; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BRAIN NEOPLASMS; FEMALE; GLIOMA; HETEROGRAFTS; HUMANS; MALE; MICE; NEOPLASTIC CELLS, CIRCULATING; PROMOTER REGIONS, GENETIC; TELOMERASE; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899512130     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-0813     Document Type: Article

References (27)

1. Imperato JP, Paleologos NA, Vick NA. Effects of treatment on longterm survivors with malignant astrocytomas. Ann Neurol 1990;28: 818-22.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
3. Mehta AI, Kanaly CW, Friedman AH, Bigner DD, Sampson JH. Monitoring radiographic brain tumor progression. Toxins 2011;3:191-200.
4. Baumann BC, Kao GD, Mahmud A, Harada T, Swift J, Chapman C, et al. Enhancing the efficacy of drug-loaded nanocarriers against brain tumors by targeted radiation therapy. Oncotarget 2013;4:64-79.
5. Baumann BC, Dorsey JF, Benci JL, Joh DY, Kao GD. Stereotactic intracranial implantation and in vivo bioluminescent imaging of tumor xenografts in a mouse model system of glioblastoma multiforme. J Vis Exp 2012;pii: 4089.
6. Kojima T, Hashimoto Y, Watanabe Y, Kagawa S, Uno F, Kuroda S, et al. A simple biological imaging system for detecting viable human circulating tumor cells. J Clin Invest 2009;119:3172-81.
7. Momburg F, Moldenhauer G, Hammerling GJ, Moller P. Immunohistochemical study of the expression of a Mr 34,000 human epitheliumspecific surface glycoprotein in normal and malignant tissues. Cancer Res 1987;47:2883-91.
8. Moldenhauer G, Momburg F, Moller P, Schwartz R, Hammerling GJ. Epithelium-specific surface glycoprotein of Mr 34,000 is a widely distributed human carcinoma marker. Br J Cancer 1987;56: 714-21.
9. Kyo S, Inoue M. Complex regulatory mechanisms of telomerase activity in normal and cancer cells: how can we apply them for cancer therapy? Oncogene 2002;21:688-97.
10. Shay JW, Bacchetti S. Asurvey of telomerase activity in human cancer. Eur J Cancer 1997;33:787-91.
11. Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008;26: 2192-7.
12. Roldan GB, Scott JN, McIntyre JB, Dharmawardene M, de Robles PA, Magliocco AM, et al. Population-based study of pseudoprogression after chemoradiotherapy in GBM. Can J Neurol Sci 2009; 36:617-22.
13. Taal W, Brandsma D, de Bruin HG, Bromberg JE, Swaak-Kragten AT, Smitt PA, et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008;113:405-10.
14. Perry A, Schmidt RE. Cancer therapy-Associated CNS neuropathology: an update and review of the literature. Acta Neuropathol 2006; 111:197-212.
15. Fizazi K, Morat L, Chauveinc L, Prapotnich D, De Crevoisier R, Escudier B, et al. High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity. Ann Oncol 2007;18:518-21.
16. Vona G, Sabile A, Louha M, Sitruk V, Romana S, Schutze K, et al. Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulatingtumor cells. Am J Pathol 2000;156:57-63.
17. Lin HK, Zheng S, Williams AJ, Balic M, Groshen S, Scher HI, et al. Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res 2010;16:5011-8.
18. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004;10:6897-904.
19. Mikolajczyk SD, Millar LS, Tsinberg P, Coutts SM, Zomorrodi M, Pham T, et al. Detection of EpCAM-negative and cytokeratin-negative circulating tumor cells in peripheral blood. J Oncol 2011;2011:252361.
20. Gradilone A, Raimondi C, Nicolazzo C, Petracca A, Gandini O, Vincenzi B, et al. Circulating tumour cells lacking cytokeratin in breast cancer: the importance of being mesenchymal. J Cell Mol Med 2011;15: 1066-70.
21. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 2009;11:R46.
22. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-15.
23. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 2009;106:13820-5.
24. Umeoka T, Kawashima T, Kagawa S, Teraishi F, Taki M, Nishizaki M, et al. Visualization of intrathoracically disseminated solid tumors in mice with optical imaging by telomerase-specific amplification of a transferred green fluorescent protein gene. Cancer Res 2004;64: 6259-65.
25. Soria JC, Gauthier LR, Raymond E, Granotier C, Morat L, Armand JP, et al. Molecular detection of telomerase-positive circulating epithelial cells in metastatic breast cancer patients. Clin Cancer Res 1999; 5:971-5.
26. Xu T, Lu B, Tai YC, Goldkorn A. A cancer detection platform which measures telomerase activity from live circulating tumor cells captured on a microfilter. Cancer Res 2010;70:6420-6.
27. Melin B, Jenkins R. Genetics in glioma: lessons learned from genomewide association studies. Curr Opin Neurol 2013;6:688-92.